Swiss Cardio Technologies AG is a spin-off from the University of Berne, Switzerland and was founded by a group of cardiovascular surgery specialists in 2008.

The company has been developing the cardioplegic solution Cardioplexol® with marketing approvals in 10 EU countries and Switzerland.

LIubeSvX4gw2acveFre2ayqVc8M scaled
heart beat scaled

Product

Swiss Cardio Technologies is the exclusive global license holder of Cardioplexol®. A novel standardized ultra-low-volume cardioplegic solution. More information can be found here.

Cardioplexol® is marketed by:
Medius AG, Neue Bahnhofstrasse 160, 4132 Muttenz, Switzerland (Switzerland)
TAW Pharma (Ireland) Limited, 104 Lower Baggot Street, Dublin 2, D02Y940, Ireland (Europe)

News

25.08.2025
Abacus Medicine Group acquires Swiss Cardio Technologies

Press release

Team

We are an experienced team of medical professionals, industrial pharmacists and business management.

Farid Taha
Farid Taha
CEO
Marc Froehlich
Marc Froehlich
Management, Program Lead
Dr. Erich
Dr. Erich Gygax
Perfusionist, Product Lead
Dr. Andreas Brutsche
Dr. Andreas Brutsche
Pharmacist, Project Manager
Dr. Neil Judge
Dr. Neil Judge
Chemist, Project Manager

Governing Board

Strategic lead, control and advisory body of experienced executives and experts that support management in long-term strategic decisions, market opportunities, innovation initiatives, and risk assessment. 

Rudolf Tschopp
Rudolf Tschopp
Chairman
Jorg Schulze
Dr. Jörg Schulze
Vice-Chairman of the Board, CCO Abacus Medicine Pharmaceuticals
Farid Taha
Farid Taha
Member of the Board
Dr. John Froehlich
Dr. John Froehlich
Member of the Board
Daniel Niehus
Daniel Niehus
Member of the Board
Prof. Dr. med. Dr. h.c. Thierry Carrel
Prof. Dr. med. Dr. h.c. Thierry Carrel
Cardiovascular surgeon, Strategic advisor
Prof. Dr. med. Jurg Schmidli
Prof. Dr. med. Jürg Schmidli
Cardiovascular surgeon, Strategic advisor

Contact

Swiss Cardio Technologies
AG
Blegistrasse 1
CH-6343 Rotkreuz

info@swisscardiotech.com